Long-term outcome in patients with juvenile dermatomyositis: A case series

Background: Follow-up of juvenile dermatomyositis (JDM) patients has demonstrated the impact of the disease on several organs in the long term. Objective: As there is little information on the long-term outcome of JDM, we aimed to assess long-term outcomes in a series of JDM patients. Methods: After selection of JDM patients, a consultation with a dermatologist and a rheumatologist was held for each patient. Cutaneous, muscle, and disease damage was assessed using different validated scores including the abbreviated Cutaneous Assessment Tool (aCAT), 8-muscle Manual Muscle Testing (MMT8), Childhood Myositis Assessment Scale (CMAS), Myositis Damage Index (MDI), Childhood Health Assessment Questionnaire (CHAQ), and Health Assessment Questionnaire (HAQ). Long-term disease outcomes were recorded including growth and pubertal development, educational and vocational achievement, and development of comorbidities. Results: Seven patients were included in the study. After a mean follow-up of 14.9 +/- 8.8 years, the mean aCAT score was 0.57 +/- 1.4 and only one patient had a positive aCAT activity score. The mean aCAT damage score was 1.4 +/- 1.3 and five (71%) patients had a score of >= 1. Five (71.4%) patients had normal muscle strength with an MMT8 score of > 72, and none had severe muscle weakness (MMT8 +/- 32, and CMAS < 35). The mean total extent of damage according to the MDI was >= 1 in five (71%) patients and mainly involved the skin. Two (29%) patients had mild disability according to the CHAQ/HAQ disability index. In terms of quality of life, no patient had a score of < 40 (1 SD below the mean for healthy controls). Conclusions: Based on validated cutaneous and musculoskeletal scores, our study demonstrated the good functional outcomes of JDM at long-term follow-up. (C) 2021 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.